Jazz Pharmaceuticals plc Net Income
Jazz Pharmaceuticals plc (JAZZ) reported Net Income of $192.80 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-03
- Jazz Pharmaceuticals plc net income (loss) attributable to parent for the quarter ending 2026-06-30 was $192.80M.
- Jazz Pharmaceuticals plc net income (loss) attributable to parent for the quarter ending 2026-03-31 was $293.10M.
- Jazz Pharmaceuticals plc net income (loss) attributable to parent for the quarter ending 2025-12-31 was $203.45M, a 6.45% increase year-over-year.
- Jazz Pharmaceuticals plc net income (loss) attributable to parent for the quarter ending 2025-09-30 was $251.41M, a 16.91% increase year-over-year.
- Jazz Pharmaceuticals plc net income (loss) attributable to parent for fiscal 2020 was $238.62M, a 54.41% decline from fiscal 2019.
- Jazz Pharmaceuticals plc net income (loss) attributable to parent for fiscal 2019 was $523.37M, a 17.06% increase from fiscal 2018.
- Jazz Pharmaceuticals plc net income (loss) attributable to parent for fiscal 2018 was $447.10M, a 8.35% decline from fiscal 2017.
- Jazz Pharmaceuticals plc net income (loss) attributable to parent for fiscal 2017 was $487.85M, a 22.94% increase from fiscal 2016.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 6 month as first filed | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 9 month as first filed | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $192.80M 10-Q · filed 2026-08-03 | $485.90M 10-Q · filed 2026-08-03 | $689.35M derived: sum of 3 quarters · filed 2026-08-03 | $940.76M derived: sum of 4 quarters · filed 2026-08-03 | |||
| 2026-03-31 | $293.10M 10-Q · filed 2026-08-03 | $496.55M derived: sum of 2 quarters · filed 2026-08-03 | $747.96M derived: sum of 3 quarters · filed 2026-08-03 | $29.46M derived: sum of 4 quarters · filed 2026-08-03 | |||
| 2025-12-31 | $203.45M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-06-08 | $454.86M derived: sum of 2 quarters · filed 2026-06-08 | -$263.64M derived: sum of 3 quarters · filed 2026-08-03 | -$356.15M DEF 14A · filed 2026-06-08 | |||
| 2025-09-30 | $251.41M 10-Q · filed 2025-11-05 | -$467.09M derived: sum of 2 quarters · filed 2026-08-03 | -$559.60M 10-Q · filed 2025-11-05 | -$368.47M derived: sum of 4 quarters · filed 2026-08-03 | |||
| 2025-06-30 | -$718.50M 10-Q · filed 2026-08-03 | -$718.47M 10-Q · filed 2025-08-06 | -$811.00M 10-Q · filed 2026-08-03 | -$811.01M 10-Q · filed 2025-08-06 | -$619.88M derived: sum of 3 quarters · filed 2026-08-03 | -$404.83M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-03-31 | -$92.50M 10-Q · filed 2026-08-03 | -$92.54M 10-Q · filed 2025-05-07 | $98.61M derived: sum of 2 quarters · filed 2026-08-03 | $313.67M derived: sum of 3 quarters · filed 2026-08-03 | $482.24M derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2024-12-31 | $191.12M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-06-08 | $406.17M derived: sum of 2 quarters · filed 2026-06-08 | $574.74M derived: sum of 3 quarters · filed 2026-06-08 | $560.12M DEF 14A · filed 2026-06-08 | |||
| 2024-09-30 | $215.06M 10-Q · filed 2025-11-05 | $383.62M derived: sum of 2 quarters · filed 2025-11-05 | $369.00M 10-Q · filed 2025-11-05 | $463.16M derived: sum of 4 quarters · filed 2026-06-08 | |||
| 2024-06-30 | $168.57M 10-Q · filed 2025-11-05 | $153.95M 10-Q · filed 2025-08-06 | $248.10M derived: sum of 3 quarters · filed 2026-06-08 | $394.92M derived: sum of 4 quarters · filed 2026-06-08 | |||
| 2024-03-31 | -$14.62M 10-Q · filed 2025-11-05 | $79.54M derived: sum of 2 quarters · filed 2026-06-08 | $226.36M derived: sum of 3 quarters · filed 2026-06-08 | $330.79M derived: sum of 4 quarters · filed 2026-06-08 | |||
| 2023-12-31 | $94.15M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-06-08 | $240.97M derived: sum of 2 quarters · filed 2026-06-08 | $345.41M derived: sum of 3 quarters · filed 2026-06-08 | $414.83M DEF 14A · filed 2026-06-08 | |||
| 2023-09-30 | $146.82M 10-Q · filed 2024-11-07 | $251.26M derived: sum of 2 quarters · filed 2024-11-07 | $320.68M 10-Q · filed 2024-11-07 | $79.95M derived: sum of 4 quarters · filed 2026-06-08 | |||
| 2023-06-30 | $104.44M 10-Q · filed 2024-11-07 | $173.86M 10-Q · filed 2024-08-01 | -$66.87M derived: sum of 3 quarters · filed 2026-06-08 | -$86.51M derived: sum of 4 quarters · filed 2026-06-08 | |||
| 2023-03-31 | $69.42M 10-Q · filed 2024-11-07 | -$171.30M derived: sum of 2 quarters · filed 2026-06-08 | -$190.95M derived: sum of 3 quarters · filed 2026-06-08 | -$156.29M derived: sum of 4 quarters · filed 2026-06-08 | |||
| 2022-12-31 | -$240.72M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-06-08 | -$260.37M derived: sum of 2 quarters · filed 2026-06-08 | -$225.71M derived: sum of 3 quarters · filed 2026-06-08 | -$224.06M DEF 14A · filed 2026-06-08 | |||
| 2022-09-30 | -$19.65M 10-Q · filed 2023-11-08 | $15.02M derived: sum of 2 quarters · filed 2023-11-08 | $16.66M 10-Q · filed 2023-11-08 | -$18.69M derived: sum of 4 quarters · filed 2026-06-08 | |||
| 2022-06-30 | $34.66M 10-Q · filed 2023-11-08 | $36.31M 10-Q · filed 2023-08-09 | $961.00K derived: sum of 3 quarters · filed 2026-06-08 | -$51.87M derived: sum of 4 quarters · filed 2026-06-08 | |||
| 2022-03-31 | $1.65M 10-Q · filed 2023-11-08 | -$33.70M derived: sum of 2 quarters · filed 2026-06-08 | -$86.54M derived: sum of 3 quarters · filed 2026-06-08 | -$449.85M derived: sum of 4 quarters · filed 2026-06-08 | |||
| 2021-12-31 | -$35.35M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-06-08 | -$88.18M derived: sum of 2 quarters · filed 2026-06-08 | -$451.50M derived: sum of 3 quarters · filed 2026-06-08 | -$329.67M DEF 14A · filed 2026-06-08 | |||
| 2021-09-30 | -$52.83M 10-Q · filed 2022-11-09 | -$416.15M derived: sum of 2 quarters · filed 2022-11-09 | -$294.32M 10-Q · filed 2022-11-09 | -$160.90M derived: sum of 4 quarters · filed 2022-11-09 | |||
| 2021-06-30 | -$363.32M 10-Q · filed 2022-11-09 | -$241.48M 10-Q · filed 2022-08-03 | -$108.07M derived: sum of 3 quarters · filed 2022-11-09 | $40.16M derived: sum of 4 quarters · filed 2022-11-09 | |||
| 2021-03-31 | $121.83M 10-Q · filed 2022-11-09 | $255.25M derived: sum of 2 quarters · filed 2022-11-09 | $403.48M derived: sum of 3 quarters · filed 2022-11-09 | $518.28M derived: sum of 4 quarters · filed 2022-11-09 | |||
| 2020-12-31 | $133.41M 10-K · filed 2021-02-23 | $281.65M derived: sum of 2 quarters · filed 2021-11-09 | $396.45M derived: sum of 3 quarters · filed 2021-11-09 | $238.62M 10-K · filed 2023-03-01 | |||
| 2020-09-30 | $148.23M 10-Q · filed 2021-11-09 | $263.04M derived: sum of 2 quarters · filed 2021-11-09 | $105.20M 10-Q · filed 2021-11-09 | $179.19M derived: sum of 4 quarters · filed 2021-11-09 | |||
| 2020-06-30 | $114.80M 10-Q · filed 2021-11-09 | -$43.03M 10-Q · filed 2021-08-03 | $30.96M derived: sum of 3 quarters · filed 2021-11-09 | $133.24M derived: sum of 4 quarters · filed 2021-11-09 | |||
| 2020-03-31 | -$157.83M 10-Q · filed 2021-11-09 | -$83.84M derived: sum of 2 quarters · filed 2021-11-09 | $18.43M derived: sum of 3 quarters · filed 2021-11-09 | $280.33M derived: sum of 4 quarters · filed 2021-11-09 | |||
| 2019-12-31 | $73.99M 10-K · filed 2021-02-23 | $176.27M derived: sum of 2 quarters · filed 2021-02-23 | $438.17M derived: sum of 3 quarters · filed 2021-02-23 | $523.37M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $102.28M 10-K · filed 2021-02-23 | $364.17M derived: sum of 2 quarters · filed 2021-02-23 | $449.38M 10-Q · filed 2020-11-02 | $608.85M derived: sum of 4 quarters · filed 2021-02-23 | |||
| 2019-06-30 | $261.90M 10-K · filed 2021-02-23 | $347.10M 10-Q · filed 2020-08-04 | $506.57M derived: sum of 3 quarters · filed 2021-02-23 | $655.88M derived: sum of 4 quarters · filed 2021-02-23 | |||
| 2019-03-31 | $85.20M 10-K · filed 2021-02-23 | $244.67M derived: sum of 2 quarters · filed 2021-02-23 | $393.99M derived: sum of 3 quarters · filed 2021-02-23 | $486.31M derived: sum of 4 quarters · filed 2021-02-23 | |||
| 2018-12-31 | $159.47M 10-K · filed 2020-02-25 | $308.79M derived: sum of 2 quarters · filed 2020-02-25 | $401.11M derived: sum of 3 quarters · filed 2020-02-25 | $447.10M 10-K · filed 2021-02-23 | |||
| 2018-09-30 | $149.32M 10-K · filed 2020-02-25 | $241.64M derived: sum of 2 quarters · filed 2020-02-25 | $287.63M 10-Q · filed 2019-11-05 | $519.84M derived: sum of 4 quarters · filed 2020-02-25 | |||
| 2018-06-30 | $92.32M 10-K · filed 2020-02-25 | $138.31M 10-Q · filed 2019-08-06 | $370.52M derived: sum of 3 quarters · filed 2020-02-25 | $434.05M derived: sum of 4 quarters · filed 2020-02-25 | |||
| 2018-03-31 | $45.99M 10-K · filed 2020-02-25 | $278.20M derived: sum of 2 quarters · filed 2020-02-25 | $341.72M derived: sum of 3 quarters · filed 2020-02-25 | $447.33M derived: sum of 4 quarters · filed 2020-02-25 | |||
| 2017-12-31 | $232.21M 10-K · filed 2019-02-26 | $295.73M derived: sum of 2 quarters · filed 2019-02-26 | $401.34M derived: sum of 3 quarters · filed 2019-02-26 | $487.85M 10-K · filed 2020-02-25 | |||
| 2017-09-30 | $63.53M 10-K · filed 2019-02-26 | $169.13M derived: sum of 2 quarters · filed 2019-02-26 | $255.64M 10-Q · filed 2018-11-06 | $372.33M derived: sum of 4 quarters · filed 2019-02-26 | |||
| 2017-06-30 | $105.60M 10-K · filed 2019-02-26 | $192.12M 10-Q · filed 2018-08-07 | $308.80M derived: sum of 3 quarters · filed 2019-02-26 | $398.63M derived: sum of 4 quarters · filed 2019-02-26 | |||
| 2017-03-31 | $86.51M 10-K · filed 2019-02-26 | $203.20M derived: sum of 2 quarters · filed 2019-02-26 | $293.03M derived: sum of 3 quarters · filed 2019-02-26 | $407.53M derived: sum of 4 quarters · filed 2019-02-26 | |||
| 2016-12-31 | $116.69M 10-K · filed 2018-02-27 | $206.52M derived: sum of 2 quarters · filed 2018-02-27 | $321.02M derived: sum of 3 quarters · filed 2018-02-27 | $396.83M 10-K · filed 2019-02-26 | |||
| 2016-09-30 | $89.83M 10-K · filed 2018-02-27 | $87.14M 10-Q · filed 2016-11-08 | $204.33M derived: sum of 2 quarters · filed 2018-02-27 | $280.14M 10-Q · filed 2017-11-07 | $272.55M 10-Q · filed 2016-11-08 | $362.90M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2016-06-30 | $114.50M 10-K · filed 2018-02-27 | $111.28M 10-Q · filed 2016-08-09 | $190.31M 10-Q · filed 2017-08-08 | $185.40M 10-Q · filed 2016-08-09 | $273.07M derived: sum of 3 quarters · filed 2018-02-27 | $361.04M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2016-03-31 | $75.81M 10-K · filed 2018-02-27 | $74.12M 10-Q · filed 2016-05-10 | $158.57M derived: sum of 2 quarters · filed 2018-02-27 | $246.53M derived: sum of 3 quarters · filed 2018-02-27 | $334.65M derived: sum of 4 quarters · filed 2018-02-27 | ||
| 2015-12-31 | $82.76M 10-K · filed 2017-02-28 | $170.72M derived: sum of 2 quarters · filed 2017-02-28 | $258.83M derived: sum of 3 quarters · filed 2017-02-28 | $329.54M 10-K · filed 2018-02-27 | |||
| 2015-09-30 | $87.96M 10-K · filed 2017-02-28 | $176.07M derived: sum of 2 quarters · filed 2017-02-28 | $246.77M 10-Q · filed 2016-11-08 | $328.39M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2015-06-30 | $88.11M 10-K · filed 2017-02-28 | $158.81M 10-Q · filed 2016-08-09 | $240.43M derived: sum of 3 quarters · filed 2017-02-28 | $266.19M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2015-03-31 | $70.70M 10-K · filed 2017-02-28 | $152.31M derived: sum of 2 quarters · filed 2017-02-28 | $178.08M derived: sum of 3 quarters · filed 2017-02-28 | $221.74M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2014-12-31 | $81.61M 10-K · filed 2016-02-23 | $107.38M derived: sum of 2 quarters · filed 2016-02-23 | $151.04M derived: sum of 3 quarters · filed 2016-02-23 | $58.39M 10-K · filed 2017-02-28 | |||
| 2014-09-30 | $25.77M 10-K · filed 2016-02-23 | $69.42M derived: sum of 2 quarters · filed 2016-02-23 | -$23.23M 10-Q · filed 2015-11-09 | $32.07M derived: sum of 4 quarters · filed 2016-02-23 | |||
| 2014-06-30 | $43.66M 10-K · filed 2016-02-23 | -$48.99M 10-Q · filed 2015-08-05 | $6.30M derived: sum of 3 quarters · filed 2016-02-23 | $81.71M derived: sum of 4 quarters · filed 2016-02-23 | |||
| 2014-03-31 | -$92.65M 10-K · filed 2016-02-23 | -$37.36M derived: sum of 2 quarters · filed 2016-02-23 | $38.05M derived: sum of 3 quarters · filed 2016-02-23 | $80.24M derived: sum of 4 quarters · filed 2016-02-23 | |||
| 2013-12-31 | $55.29M 10-K · filed 2015-02-24 | $130.70M derived: sum of 2 quarters · filed 2015-02-24 | $172.89M derived: sum of 3 quarters · filed 2015-02-24 | $216.31M 10-K · filed 2016-02-23 | |||
| 2013-09-30 | $75.41M 10-K · filed 2015-02-24 | $117.59M derived: sum of 2 quarters · filed 2015-02-24 | $161.02M 10-Q · filed 2014-11-04 | $361.57M derived: sum of 4 quarters · filed 2015-02-24 | |||
| 2013-06-30 | $42.19M 10-K · filed 2015-02-24 | $85.61M 10-Q · filed 2014-08-05 | $286.16M derived: sum of 3 quarters · filed 2015-02-24 | $319.37M derived: sum of 4 quarters · filed 2015-02-24 | |||
| 2013-03-31 | $43.42M 10-K · filed 2015-02-24 | $243.98M derived: sum of 2 quarters · filed 2015-02-24 | $277.19M derived: sum of 3 quarters · filed 2015-02-24 | $304.33M derived: sum of 4 quarters · filed 2015-02-24 | |||
| 2012-12-31 | $200.55M 10-K · filed 2014-02-25 | $233.76M derived: sum of 2 quarters · filed 2014-02-25 | $260.90M derived: sum of 3 quarters · filed 2014-02-25 | $288.59M 10-K · filed 2015-02-24 | |||
| 2012-09-30 | $33.21M 10-K · filed 2014-02-25 | $60.35M derived: sum of 2 quarters · filed 2014-02-25 | $88.03M 10-Q · filed 2013-11-05 | $125.51M derived: sum of 4 quarters · filed 2014-02-25 | |||
| 2012-06-30 | $27.14M 10-K · filed 2014-02-25 | $54.83M 10-Q · filed 2013-08-06 | $92.30M derived: sum of 3 quarters · filed 2014-02-25 | $124.78M derived: sum of 4 quarters · filed 2014-02-25 | |||
| 2012-03-31 | $27.68M 10-K · filed 2014-02-25 | $65.15M derived: sum of 2 quarters · filed 2014-02-25 | $97.64M derived: sum of 3 quarters · filed 2014-02-25 | $130.84M derived: sum of 4 quarters · filed 2014-02-25 | |||
| 2011-12-31 | $37.47M 10-K · filed 2012-02-28 | $69.95M derived: sum of 2 quarters · filed 2012-11-09 | $103.16M derived: sum of 3 quarters · filed 2012-11-09 | $124.98M 10-K · filed 2014-02-25 | |||
| 2011-09-30 | $32.48M 10-Q · filed 2012-11-09 | $65.68M derived: sum of 2 quarters · filed 2012-11-09 | $87.51M 10-Q · filed 2012-11-09 | $124.98M derived: sum of 4 quarters · filed 2013-02-26 | |||
| 2011-06-30 | $33.20M 10-Q · filed 2012-08-07 | $55.03M 10-Q · filed 2012-08-07 | $92.50M derived: sum of 3 quarters · filed 2013-02-26 | $124.98M derived: sum of 4 quarters · filed 2013-02-26 | |||
| 2011-03-31 | $21.83M 10-Q · filed 2012-05-08 | $59.30M derived: sum of 2 quarters · filed 2013-02-26 | $91.78M derived: sum of 3 quarters · filed 2013-02-26 | $124.98M derived: sum of 4 quarters · filed 2013-02-26 | |||
| 2010-12-31 | $37.47M 10-K · filed 2013-02-26 | $24.46M 10-K · filed 2012-02-28 | $69.95M derived: sum of 2 quarters · filed 2013-02-26 | $103.16M derived: sum of 3 quarters · filed 2013-02-26 | $32.78M 10-K · filed 2013-02-26 | ||
| 2010-09-30 | $32.48M 10-K · filed 2013-02-26 | $13.24M 10-Q · filed 2011-11-08 | $65.68M derived: sum of 2 quarters · filed 2013-02-26 | $8.32M 10-Q · filed 2011-11-08 | |||
| 2010-06-30 | $33.20M 10-K · filed 2013-02-26 | -$6.39M 10-Q · filed 2011-08-03 | -$4.92M 10-Q · filed 2011-08-03 | ||||
| 2010-03-31 | $21.83M 10-K · filed 2013-02-26 | $1.46M 10-K · filed 2012-02-28 | |||||
| 2009-12-31 | -$6.84M 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |